Abstract
Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Keywords: Amyloid, Proteases, Alzheimers Disease
Current Pharmaceutical Design
Title: Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease
Volume: 8 Issue: 28
Author(s): Frauke Schimmoller, Jeffrey N. Higaki and Barbara Cordell
Affiliation:
Keywords: Amyloid, Proteases, Alzheimers Disease
Abstract: Alzheimers disease is an age-related neurodegenerative disease which causes global loss of cognitive function. Drug treatment for Alzheimers disease has been limited to agents that ameliorate behavioral symptoms but these agents are without effect on disease progression. Rational drug design for the treatment of Alzheimers disease now seems possible. As a result of major advances in medical research in this area, knowledge of the etiology of Alzheimers disease is rapidly being understood. This information has uncovered relevant and novel targets for treatment. At the center of the etiological progression of this disease is β-amyloid. A substantial body of evidence strongly suggests that this small protein is critical to the development of Alzheimers disease. The β-amyloid protein is generated by two different proteolytic cleavages. Recently, the proteases responsible for producing the β-amyloid protein have been identified. The proteases represent viable targets for therapeutic intervention against Alzheimers disease. In this review, we describe the biological characteristics of the β-amyloid-forming proteases in the context of pharmaceutical development.
Export Options
About this article
Cite this article as:
Schimmoller Frauke, Higaki N. Jeffrey and Cordell Barbara, Amyloid Forming Proteases: Therapeutic Targets for Alzheimers Disease, Current Pharmaceutical Design 2002; 8 (28) . https://dx.doi.org/10.2174/1381612023392658
DOI https://dx.doi.org/10.2174/1381612023392658 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Premature Cardiovascular Disease in Women with Lupus and Relationship to Disease Severity
Current Women`s Health Reviews Editorial:
Current Diabetes Reviews Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Role of Iron Deficiency and Overload in the Pathogenesis of Diabetes and Diabetic Complications
Current Medicinal Chemistry Metabolomic Insight into Lipid and Protein Profile in Diabetes Using Mass Spectrometry
Mini-Reviews in Medicinal Chemistry Contractile Mechanisms in Diabetes-Related Erectile Dysfunction
Current Pharmaceutical Design Current Status of CETP Inhibitors in the Treatment of Hyperlipidemia: An Update
Current Clinical Pharmacology Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Sleep Apnea and Coronary Heart Disease: From Dusk Till Dawn and Further
Current Respiratory Medicine Reviews Wnt Signaling Pathway in Schizophrenia
CNS & Neurological Disorders - Drug Targets Nephrotoxicity Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Drug Safety Non-Traditional Systemic Treatments for Diabetic Retinopathy: An Evidence-Based Review
Current Medicinal Chemistry Adiponectin - A Novel Anti-Atherogenic Factor in the Metabolic Syndrome: Mechanisms of Action and Therapeutic Potential
Vascular Disease Prevention (Discontinued) Comparison Between Computed Tomography Angiography and Digital Subtraction Angiography in Critical Lower Limb Ischemia
Current Medical Imaging The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Structural Basis of Infectious and Non-Infectious Amyloids
Current Alzheimer Research Imaging of Organ Metabolism in Obesity and Diabetes: Treatment Perspectives
Current Pharmaceutical Design Ceruloplasmin, the Unique Multi-Copper Oxidase of Vertebrates
Protein & Peptide Letters Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Neurodegeneration and Neuroinflammation in Diabetic Retinopathy: Potential Approaches to Delay Neuronal Loss
Current Neuropharmacology